A
Alector Inc (ALEC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$2.57
+0.03 (+1.18%)
Market Cap: $378.15M
Last updated: Nov 17, 2026 at 11:04 AM ET
Alector Inc (ALEC) P/E Ratio & Valuation Multiples
Alector (ALEC) trades at 7.3x trailing earnings and 1.7x sales. Its P/S of 1.7x is below its 5-year median of 5.1x. Its forward P/E is 8.5x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 14.1% lower over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 7.3x |
| Forward P/E | 8.5x |
| Price to sales | 1.7x |
| Price to book | 2.5x |
| EV/EBITDA | 4.4x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.7x | 5.1x | N/A |
| P/B | 2.5x | 3.0x | N/A |
Valuation History
Over the 7 year ends shown, its P/S ranged from 1.8x in 2024 to 371.9x in 2019.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $1.56 | 7.5x | 5.2x |
| 2024 | $1.89 | 1.8x | 1.5x |
| 2023 | $7.98 | 6.9x | 5.0x |
| 2022 | $9.23 | 5.7x | 3.6x |
| 2021 | $20.65 | 8.1x | 5.6x |
| 2020 | $15.13 | 55.6x | 4.5x |
| 2019 | $17.23 | 371.9x | 6.0x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ALEC
What is ALEC's forward P/E ratio?
Alector has a forward P/E ratio of 8.5x.
Is ALEC stock overvalued?
GNG's valuation label for ALEC is Overvalued.
What is ALEC's price to sales ratio?
Alector has a price to sales ratio of 1.7x.
ALEC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors